TriSalus Life Sciences Inc (TLSI) 뉴스

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with...

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients...

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery...

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Call Scheduled for Thursday, November 14, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to...

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with...

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with...

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (117%; p=0.004...

TriSalus Reports Q2 2024 Financial Results and Business Update

Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to...

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its...

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with...

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with...

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

– Hepatic arterial infusion (HAI) of nelitolimod has been well tolerated and associated with encouraging immunologic activity in patients with...

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with...